Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1127 of 6351
-
Triple threat against melanoma: drug + supercharged immune cells show promise
Disease control CompletedThe purpose of this study is to find out more about the effects of an investigational combination of medicines, which includes special immune cells (T-cells). A T-cell is a type of lymphocyte, or white blood cell. Lymphocytes are a kind of white blood cell that protect the body …
Phase 2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Breast milk from donors vs. formula: which builds a better brain for tiny babies?
Disease control CompletedThe Milk Trial seeks to determine the effect on neurodevelopmental outcomes at age 22-26 months of donor human milk as compared to preterm infant formula as the in-hospital diet for infants whose mothers choose not to provide breast milk or are able to provide only a minimal amou…
Phase 3 • Sponsor: NICHD Neonatal Research Network • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New hope for rare HIV-2: drug combo shows promise
Disease control CompletedThe HIV-2 is less common ie 1-2 million people in West Africa. HIV-2 does have the same sensitivity to antiretroviral treatment (ART) compared to HIV-1. The ART strategies that are appropriate for the HIV-1 infection are not as effective for HIV-2. Classical triple therapy includ…
Phase 2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug cocktail shows promise for tough lymphomas
Disease control CompletedThis is a phase 1/2 multicenter study to assess the safety and effectiveness of brentuximab vedotin and bendamustine, when given together, in patients with Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma (ALCL) that has either returned or did not respond to initial treatment(s…
Phase 1/2 • Sponsor: Columbia University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for lung cancer patients with rare gene mutations
Disease control Recruiting nowThe purpose of this phase II study is to find out what effects cabozantinib (XL184) has, good and/or bad, in patients whose tumors one of the following gene changes RET, ROS1, or NTRK fusion, or increased MET or AXL activity. A phase II study looks at how effective a medication …
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a Two-Drug combo tame a rare nerve and blood disorder?
Disease control CompletedPOEMS syndrome is a rare form of B cell dyscrasia combining a proliferation usually of plasma cells, a polyneuropathy, osteocondensing bone lesions and multiple other clinical signs. Lenalidomide appears to be particularly efficient in this pathology. The investigators propose a…
Phase 2 • Sponsor: University Hospital, Limoges • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Could less radiation be enough? new trial tests tailored therapy for kids with brain tumors
Disease control CompletedThis phase II trial studies how well chemotherapy followed by radiation therapy work in treating younger patients with newly diagnosed central nervous system germ cell tumors that have not spread to other parts of the brain, spinal canal, or body (localized). Drugs used as chemot…
Phase 2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Promising combo tackles relapsed myeloma in early trial
Disease control CompletedThe purpose of this study is to establish the safety profile of daratumumab when given in combination with Lenalidomide and dexamethasone in participants with relapsed or relapsed and refractory Multiple Myeloma (MM).
Phase 1/2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New combo therapy aims to boost blood counts in bone marrow failure
Disease control Recruiting nowThis phase II trial studies methylprednisolone, horse anti-thymocyte globulin, cyclosporine, filgrastim, and/or pegfilgrastim or pegfilgrastim biosimilar in treating patients with aplastic anemia or low or intermediate-risk myelodysplastic syndrome. Horse anti-thymocyte globulin …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Which dose of vandetanib works best for thyroid cancer?
Disease control CompletedThe purpose of this study is to give patients with medullary thyroid cancer either 300mg/day or 150mg/day vandetanib and compare how well each dose affects how their cancer responds. It will also help the investigators understand the side effects of different doses in these patie…
Phase 4 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New chemo drug could mean fewer shots for kids with leukemia
Disease control OngoingThis study is being conducted to learn about the effects of SC-PEG, which is a new form of a chemotherapy drug called asparaginase. Asparaginase is used to treat ALL and lymphoblastic lymphoma. The standard form of asparaginase, called Elspar, is given in the muscle once a week f…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New ALK inhibitor ensartinib tested in first human trial for lung cancer
Disease control CompletedThis is the first human study to use X-396 (ensartinib), a drug being developed for treatment of advanced cancers. The initial purpose of the study is to determine the largest amount of X-396 that can be safely given to humans (the maximum tolerated dose). Once the recommended Ph…
Phase 1/2 • Sponsor: Xcovery Holdings, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Could a Triple-Drug cocktail prevent multiple myeloma?
Disease control CompletedBackground: * Multiple myeloma is a blood cancer that affects the plasma cells. These cells help produce antibodies and fight infection. Smoldering multiple myeloma (SMM) is a related condition that may develop into multiple myeloma. The current standard of care for SMM is close…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug candidate targets Hard-to-Treat blood cancers
Disease control OngoingThe primary purpose of this study is to measure the response rate in participants with the myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF) when treated with LY2784544, including those who have demonstrated an into…
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Single dose of radiation during lumpectomy may control early breast cancer
Disease control OngoingThis phase IV trial studies the side effects of intraoperative radiation therapy and how well it works in treating patients with breast cancer undergoing breast-conserving surgery. Delivering radiation one time to the area where the tumor was removed while the patient is still in…
Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Weekly shot could help kids with hemophilia b avoid bleeding
Disease control CompletedThis trial is conducted in Asia, Europe and North America. The aim of the trial is to evaluate safety, efficacy and pharmacokinetics (the exposure of the trial drug in the body) of NNC-0156-0000-0009 (nonacog beta pegol, N9-GP) in previously treated children with Haemophilia B.
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug combo aims to tackle pancreatic cancer in patients with inherited gene mutations
Disease control OngoingThis randomized phase II trial studies how well veliparib together with gemcitabine hydrochloride and cisplatin works compared to gemcitabine hydrochloride and cisplatin alone in treating patients with pancreatic cancer that has spread from where it started to nearby tissue or ly…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Eye-Strengthening light therapy tested to halt blinding cornea disease
Disease control OngoingThe purpose of this study is to determine whether corneal collagen crosslinking is effective in the treatment of progressive keratoconus.
Phase 3 • Sponsor: Sahlgrenska University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Can new imaging and genetics unlock the secrets of heart attacks?
Knowledge-focused Recruiting nowCoronary artery disease is one of the most common causes of illness and death. It develops when fatty deposits, known as plaques, build up in the arteries that supply blood to the heart. These plaques can gradually narrow the arteries and reduce blood flow, causing symptoms such …
Sponsor: University of Oxford • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC
-
Hope for hepatitis c relapsers: new Triple-Drug combo shows promise
Disease control CompletedThis study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b and Ribavirin (RBV) in patients with genotype 2 hepatitis C, who relapsed after previous treatment.
Phase 3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC